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Abstract. The line between vascular dementia (VaD) and Alzheimer’s disease (AD) is often blurred. In this study we investigated
whether adenosine A2A receptor (A2AR) expression can be used to differentiate between VaD and AD. We evaluated the expression
of this receptor in the peripheral blood mononuclear cells of patients with VaD, mild cognitive impairment, AD, and controls.
We found statistically significant lower levels of A2AR mRNA in VaD compared to AD subjects. These data suggest that A2AR
expression may help in the differential diagnosis between VaD and AD.
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Although Alzheimer’s disease (AD) might be best
designated as a purely degenerative disease in whose
pathogenesis amyloid- plays a key role, it is acknowl-
edged that in elderly patients (>65 years) there is an
increased likelihood of other neuropathological abnor-
malities including cerebrovascular lesions [1–3]. Over
the last years, there has been accumulating evidence
that the previously held sharp distinction between AD
and vascular dementia (VaD) may not be so clear-cut,
especially in old age [4].
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VaD is the second most common cause of dementia
after AD. The diagnosis of VaD is based on a number
of criteria: cognitive deficits, history of stroke and/or
focal vascular neurological deficits, and temporal asso-
ciation between stroke and onset of dementia [5]. VaD
arises as a consequence of ischemic insults such as
hemorrhage and hypoperfusion that trigger neurode-
generation by depriving nerve cells of oxygen and
glucose [6, 7]. Such deprivation results in the deple-
tion of nerve cell energy supplies, leading to membrane
depolarization, followed by an excessive release of
glutamate which activates the N-methyl-D-aspartate
receptor (NMDAR). This allows the influx of toxic lev-
els of Ca2+ into nerve cells, which, in turn, activates
intracellular calcium-dependent enzymes [8, 9].
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The purine ribonucleoside adenosine (Ado) is a
naturally occurring metabolite that is ubiquitously
distributed throughout the body as a metabolic
intermediary. Intra- and extracellular Ado levels
rise in response to physiological stimuli and with
metabolic/energetic perturbations, inflammatory chal-
lenges, and tissue injury [10, 11].
The physiological responses to Ado take place as a
result of the binding and activation of different trans-
membrane receptors: the high-affinity A1 and A2A
(A2AR) receptors, the low-affinity A2B receptor, or the
low-abundance A3 receptor [12].
It has been demonstrated that A2AR is able to prevent
amyloid--induced synaptotoxicity in animal models
and cell cultures [13]. Moreover A2AR has been shown
to control NMDA currents and glutamate outflow in the
hippocampus [14, 15].
Contrasting data have been reported so far on the
beneficial/detrimental effects of A2AR on brain cells
[16]. The blockade of A2AR alleviates the long-term
burden of brain disorders such as ischemia, epilepsy,
Parkinson’s disease, or AD [14, 17–19]. On the other
hand, agonists of A2AR can protect the central nervous
system against several insults, including ischemia and
excitotoxins [20, 21].
In the periphery, A2AR contributes to coronary
endothelial dilatation in mice [22], can inhibit endothe-
lial apoptosis [23], and preserves vascular reactivity
following hemorrhagic shock in rats [24].
Finally, increasing evidence supports the notion that
A2AR is implicated in the downregulation of inflam-
mation [12, 25].
We recently investigated A2AR gene expression and
protein levels in the peripheral blood mononuclear
cells (PBMCs) of patients with amnestic mild cognitive
impairment (aMCI), multiple cognitive domain MCI
(mcdMCI), outright AD, and age-matched healthy
controls. We found the highest levels of A2AR in aMCI,
suggesting an involvement of the Ado system in the
early stages of AD [26].
The aim of the present study was two-fold: a) to
confirm our previous findings in a larger sample of new
recruited patients, and b) to determine the expression
of the A2AR in the PBMCs from VaD subjects in order
to investigate its potential role as an easily accessible
biomarker in the differential diagnosis between AD
and VaD.
The study involved 40 VaD, 85 AD, 13 aMCI,
58 mcdMCI, and 76 non demented gender-matched
controls (Table 1). Subjects were recruited from out-
patients attending the Geriatric Unit of the Fondazione
IRCCS Ca’ Granda of Milan, Italy. VaD was diagnosed
according to NINCDS-AIREN criteria [27]. All AD
patients fulfilled the NINCDS-ARDA criteria [28]. A
computed tomography or magnetic resonance imaging
scan corroborated the diagnosis of dementia. On the
basis of their cognitive characteristics, MCI patients
were classified as aMCI or mcdMCI. Disease severity
was evaluated using Mini-Mental State Examination
score. Controls were assessed to exclude the pres-
ence of neurological and cognitive disorders of any
kind. All participants gave their informed consent to
the study, which had been previously approved by the
local ethics committee. Blood from all patients and
controls was collected between 8 and 9 a.m., after a 6-
hour fast. Caffeine consumption was about 80 mg/die
(one cup of coffee) or less. Apolipoprotein E (ApoE)
genotypes were determined in all samples for which
DNA was available [29]. PBMCs were isolated, RNA
was extracted, and real time PCR was carried out as
previously described [26] in 40 VaD, 85 AD, 13 aMCI,
58 mcdMCI, and 76 control subjects. The proteins
of 24 VaD, 48 AD, 13 aMCI, 24 mcdMCI, and 21
control subjects were extracted and A2AR levels were
measured by western blot as previously described [26].
The statistical analyses were performed by means
of the SPSS statistical package (SPSS version 20,
Chicago, IL). mRNA and protein levels, expressed as
mean ± standard error, were compared across groups
by using the one-way ANOVA, with Student’s t-test
applied to paired comparisons. A p value <0.05 was
considered statistically significant. The predictive effi-
cacy of A2AR was assessed using the area under the
curve (AUC) generated by a receiver operating char-
acteristic (ROC) analysis.
We found different A2AR mRNA levels in
VaD (1.04 ± 0.14), mcdMCI (1.42 ± 0.12), con-
trol (1.66 ± 0.16), AD (1.92 ± 0.17), and aMCI
(3.05 ± 0.92) subjects, with a significant linear
increase from VaD to aMCI patients regardless of age
and gender (p < 0.001). Comparing the gene expression
of each group to controls, we did not find signifi-
cant differences; on the contrary, the gene expression
in the PBMCs of AD and VaD subjects was signifi-
cantly different (p < 0.001) (Fig. 1). Interestingly, ROC
analysis showed that A2AR identifies VaD from a het-
erogeneous group composed of VaD and AD patients
with AUC 0.73 (95% CI, 0.63–0.83). Along this line,
A2AR density displayed an increased trend from VaD
(0.44 ± 0.03) to aMCI (0.59 ± 0.09) subjects, with
intermediate levels found in mcdMCI (0.47 ± 0.04),
AD (0.49 ± 0.04), and control (0.59 ± 0.04) subjects.
The frequency of ApoE ε4 was in line with previ-
ously published data [30, 31]. A2AR gene expression
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Table 1
Participant characteristics
VaD AD aMCI mcdMCI CT
No. of participants 40 85 13 58 76
Age (mean ± standard error) 82.6 ± 0.9 78.3 ± 0.6 78.9 ± 2.2 78.6 ± 0.8 80.8 ± 0.8
MMSE (mean ± standard error) 18.3 ± 1.2 18.6 ± 0.9 26.0 ± 1.4 24.8 ± 0.6 27.9 ± 0.2
ApoE 4-/4+ 29/10 41/44 9/4 39/18 68/8
Fig. 1. A) Scatter plot of A2AR mRNA levels in peripheral blood
mononuclear cells (PBMCs) from vascular dementia (VaD), mul-
tiple cognitive domain MCI (mcdMCI), control (CT), Alzheimer’s
disease (AD), and amnestic mild cognitive impairment (aMCI) sub-
jects quantified by means of the 2−Ct method (the lines represent
the mean value for each group). ∗p < 0.001 versus AD; #p < 0.05 ver-
sus aMCI. B) Representative picture of the western blot analysis of
the A2AR densities in PBMCs extracts, run in duplicate, from one
subject respectively of VaD, CT, AD, and aMCI groups.
and receptor density were similar in both ε4 carriers
and non-carriers in each group of subjects, indicating
that the ε4 allele does not participate in the modulation
of this gene (data not shown).
This study confirms, in a larger sample of subjects,
our previous finding that A2AR expression is upreg-
ulated in the peripheral cells of aMCI but not AD
subjects, supporting an involvement of the Ado sys-
tem in the early stages of AD. It also shows that A2AR
expression is lower in the PBMCs of subjects with
VaD than AD, highlighting its possible relevance as
a biomarker that may help differentiate two forms of
dementia that are often closely associated. ROC analy-
sis data show that A2AR possesses a moderate degree of
sensitivity and specificity for identifying VaD patients
from a heterogeneous group composed of VaD and AD
patients.
The altered A2AR levels in these two types of
dementia could be due to the action of A2AR on the
conductance of the NMDAR [14, 15] and on glutamate
outflow [32], both of which are important mechanisms
in the pathophysiology of VaD [9] but are also recog-
nized as key features of early AD [33].
The lower A2AR expression in VaD compared to AD
subjects seems to suggest a differential role of the Ado
system in these dementias.
A2AR represents the main Ado receptor involved
in inflammation and it is interesting to note that other
inflammatory biomarkers show differences in VaD and
AD (e.g., 1-globulin and 2-globulin in the serum
[34] and C3a and C4a in the cerebrospinal fluid [35]).
On the other hand, the A2AR levels reduction in
VaD could be a defense mechanism since it has
been demonstrated that pharmacologic inactivation or
genetic deletion of A2AR reduces neuronal injury after
global and focal cerebral ischemia in many animal
models [19, 36, 37]. Moreover there are some very
robust studies showing that Ado receptors control the
dynamics of the brain vasculature [38].
Such evidences underline the complexity of A2AR
and suggest that the overall effect of adenosine acting
at A2AR results from the interplay of several systems
activated by A2AR.
We found a significant difference across groups in
mRNA levels but only a trend in receptor densities.
This could be due to the fact that the number of spec-
imens analyzed by western blot was less than that
analyzed by qPCR. Moreover mRNA steady-state lev-
els do not always strictly correlate with protein levels
since post-transcriptional changes work together with
transcription to achieve the final expression pattern
[39, 40].
From our results it can be concluded that A2AR may
play an important but differential role in both types
of dementia: its upregulation in the preclinical stages
of AD could counterbalance the existing inflammatory
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state and its downregulation in VaD could reflect the
effects of A2AR on the brain vasculature. It can there-
fore be suggested that A2AR could serve as a biomarker
in the differential diagnosis between VaD and AD.
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